Julien (on behalf of Paul Matteis)'s questions to Xenon Pharmaceuticals Inc (XENE) leadership • Q3 2024
Question
Julien, on behalf of Paul Matteis, asked for an update on clinical trial enrollment dynamics and inquired about the potential read-through from the investigator-sponsored study (IST) in Major Depressive Disorder (MDD) to Xenon's own Phase III program.
Answer
CEO Ian Mortimer confirmed that the Phase III epilepsy program enrollment is on track for the H2 2025 data readout for X-TOLE2. He stated the MDD IST has no direct read-through to their larger, company-sponsored Phase III trials. CMO Dr. Christopher Kenney added the IST is underpowered for clinical endpoints like MADRS but is powered for fMRI measures and will provide useful tolerability data.